Obsidian Therapeutics is a clinical-stage biotechnology specializing in engineered cell and gene therapies with a mission to deliver transformative outcomes for patients with intractable diseases. The company utilizes drug-responsive domains for controlled protein function in therapeutics, aiming for targeted treatment solutions. Obsidian Therapeutics was founded by Michael Gilman, Steve Shamah, and Tariq Kassum in 2015 and is headquartered in Cambridge, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/03/2024 | Series C | $160.5MM | $xx.xx | $507.38MM | Wellington Management, Foresite Capital, Janus Henderson Investors, Novo Holdings, Paradigm BioCapital, RTW Investments, T. Rowe Price Associates, Woodline Partners, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCG Crossover Management, Samsara, Surveyor Capital | |
Price per Share
$xx.xx
Shares Outstanding
84,567,145
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Wellington Management, Foresite Capital, Janus Henderson Investors, Novo Holdings, Paradigm BioCapital, RTW Investments, T. Rowe Price Associates, Woodline Partners, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCG Crossover Management, Samsara, Surveyor Capital
|
||||||
09/09/2021 | Series B | $115.04MM | $xx.xx | $278.56MM | TCG Crossover Management, RA Capital Management, Surveyor Capital, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal Life Sciences, Samsara, Soleus Capital, Atlas Venture, Vertex Ventures HC, Amgen Ventures, Bristol Myers Squibb, Vertex Pharmaceuticals, Blue Owl Capital | |
Price per Share
$xx.xx
Shares Outstanding
76,187,917
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
TCG Crossover Management, RA Capital Management, Surveyor Capital, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal Life Sciences, Samsara, Soleus Capital, Atlas Venture, Vertex Ventures HC, Amgen Ventures, Bristol Myers Squibb, Vertex Pharmaceuticals, Blue Owl Capital
|
||||||
12/06/2017 | Series A-3 | $7.27MM | $xx.xx | $116.85MM | GV, Atlas Venture, Takeda Ventures, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments, ShangPharma Innovation, Bristol Myers Squibb | |
Price per Share
$xx.xx
Shares Outstanding
4,948,612
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
GV, Atlas Venture, Takeda Ventures, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments, ShangPharma Innovation, Bristol Myers Squibb
|
||||||
12/06/2017 | Series A-2 | $12.03MM | $xx.xx | $116.85MM | GV, Atlas Venture, Takeda Ventures, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments, ShangPharma Innovation, Bristol Myers Squibb | |
Price per Share
$xx.xx
Shares Outstanding
12,025,212
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
GV, Atlas Venture, Takeda Ventures, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments, ShangPharma Innovation, Bristol Myers Squibb
|
||||||
12/06/2017 | Series A-1 | $30.2MM | $xx.xx | $116.85MM | GV, Atlas Venture, Takeda Ventures, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments, ShangPharma Innovation, Bristol Myers Squibb | |
Price per Share
$xx.xx
Shares Outstanding
26,747,257
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
GV, Atlas Venture, Takeda Ventures, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments, ShangPharma Innovation, Bristol Myers Squibb
|